ReviewFrontiers in nutrition2025
From functional foods to immunotherapeutic agents: mechanistic insights into medicinal mushroom bioactives in chronic inflammation management.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Immunomodulatory Effects of Zinc and Selenium-EnrichedFood science & nutrition · 2026Article
- Pleiotropic Bioactivity of Caterpillar Fungus, Orange Cordyceps, and Cordycepin: Insight from Integrated Network Pharmacology and Food and Drug Regulatory Framework.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mushroom-derived polysaccharides as broad-spectrum antimicrobial agents: mechanisms, structural modifications, and therapeutic potential.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammation underlies numerous complex diseases, yet current therapeutic strategies show limited efficacy and safety profiles. Despite extensive preclinical evidence, the mechanistic understanding and clinical translation of medicinal mushroom bioactives remain inadequately characterized. Objective: This review systematically evaluates the immunoregulatory mechanisms of mushroom-derived bioactive compounds and establishes a comprehensive framework for their therapeutic application in chronic inflammatory diseases. Methods: We analyzed mechanistic evidence for four major compound classes: polysaccharides (β-glucans), triterpenoids, phenolic compounds, and bioactive peptides, examining their effects on immune cell populations and signaling pathways. Results: These bioactives demonstrate multi-target anti-inflammatory activity by modulating key cellular mediators (macrophages, regulatory T cells, natural killer cells) and critical signaling cascades (NF-κB, MAPK, NLRP3 inflammasome, Nrf2/HO-1). Novel therapeutic targets including gasdermin-mediated pyroptosis provide additional intervention opportunities. However, clinical translation faces significant challenges: poor bioavailability, lack of standardization, and undefined dose-response relationships. Conclusion: Advanced delivery systems (nanoformulations, structural optimization) and precision nutrition approaches through personalized immune profiling offer promising solutions to overcome translational barriers. This analysis provides evidence-based rationale for advancing medicinal mushrooms from traditional functional foods to standardized immunotherapeutic agents for chronic inflammation management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.